Putting The Deep Freeze On Prostate Cancer
Studies have shown that 65% of men receiving a prostate cancer diagnosis are over the age of 65. Many of these patients are unable to undergo surgery or radiation treatment due to advanced age or other medical conditions. Cryotherapy (also known as cryosurgery or cryoablation) is proving to be a viable option for these men. Recent research at Crittenton Hospital in Rochester, MI, showed that more than 86% of all prostate cryoablation patients in their study experienced a successful treatment. In addition, the success rates of primary cryotherapy for prostate cancer are at least equivalent to that of conventional invasive radical surgery and radiation treatments.
Additional advantages of cryotherapy over other treatment options include:
Because it is effective only in small areas, cryotherapy is not used to treat prostate cancer that has spread outside the gland, or to distant parts of the body.
While cryotherapy has been well received with patients, cryosurgery for the prostate gland can have side effects including obstructed urine flow, incontinence, impotence, or injury to the rectum. Side effects are usually temporary, but impotence is more common with cryotherapy than with surgery or radiation.
Cryotherapy is typically performed when the prostate volume is 50 grams or less in size. If the prostate is larger, the patient may be placed on hormone therapy to block production of male hormones, causing the prostate to shrink.
During the minimally invasive cryotherapy procedure, multiple cryoablation needles are inserted into the prostate through the perineum (the area between the anus and scrotum) while the patient is under anesthesia. An ultrasound probe is inserted into the rectum in order for the urologist to view the prostate and the entire freezing process during the procedure.
Because the urethra passes through the prostate gland, a warming catheter is used to protect it from freezing. Thermal sensor needles monitor the temperature within and around the prostate to ensure that the prostate is being frozen to temperatures less than -40° C while the adjacent areas of the rectum and other organs remain unfrozen. This safeguard dramatically lowers the chance of incontinence, rectal fistulae or other side effects.
When the cryoablation needles and temperature sensors are in place, a freezing agent, argon gas, is circulated through the cryoablation needles to create temperatures of -40° C or colder. This creates a lethally cold iceball that freezes the prostate and the cancer cells in it. The thawing process, which is what actually ruptures and kills the cancer cells in the prostate gland, is initiated. This freeze-thaw process is repeated to ensure all cancerous cells are destroyed and to help prevent future prostate cancer recurrence. The dead tissue is reabsorbed or remains in the body as harmless scar tissue.
When the freeze-thaw process is finished, the warming catheter is removed and a urinary catheter is inserted to help with any temporary urinary incontinence. The urinary catheter is typically removed after two or three days unless incontinence persists.
For more information about cryotherapy, contact Alliance Urology Specialists at 336-274-1114.
Return to newsletter page